Study of NGM120 for weight loss in colorectal cancer
Part of Cancer, Digestive system clinical trials.
This study tests an experimental drug called NGM120 for people with colorectal cancer who are losing weight (a condition called cancer cachexia). It is a placebo-controlled trial, meaning some participants will receive the drug and some will receive a placebo, to see if the drug helps stop or reverse this weight loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with colorectal cancer that is still active.
- You must have experienced significant weight loss (cachexia) recently.
- You cannot have a temporary, treatable reason for not eating that explains your weight loss (like an infection).
- You cannot be on a feeding tube or IV nutrition at the start of the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine (QLS2319) to see if it’s safe and can help people with cancer-related weight loss and muscle loss (cachexia). It’s for people whose daily activities aren’t severely limited by their cancer.
This study tests a special form of megestrol acetate (a medicine that can help with appetite and weight gain) in people with advanced digestive system cancers who are about to start or are already taking a type of targeted therapy called a TKI. The goal is to see if it helps with cancer-related weight loss and wasting (cachexia).
This trial tests a new drug called JMT203 for people with cancer-related weight loss (cachexia). It aims to see if the drug can help prevent or reverse weight loss in patients with certain solid tumors who are also receiving or have recently completed anti-cancer therapy.
This study tests an investigational drug called INB301 to see if it can help cancer patients who have lost significant weight due to their disease. The drug targets a protein involved in appetite and muscle loss.
This Phase 1 trial tests a new drug called GB18 to help cancer patients who have experienced significant weight loss and muscle wasting—a condition called cancer cachexia. The drug works by targeting a specific protein involved in weight loss, and researchers want to learn if it can help patients regain weight and strength while also being safe.
This study looks at different types of weight loss (cachexia) in people with advanced lung, pancreatic, or colorectal cancer. Researchers want to find patterns to better understand and treat it. You can join even if you haven't lost weight yet.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.